Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.55 |
| ▸ | FAP | Q12884 | 12/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PTPRA | P18433 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167734 | 1.00 | DPP4 (0.55) | DPP4FAPDPP7DPP8DPP9 | |
| Trifluoroacetic Acid SCHEMBL4163377 | 0.86 | DPP4 (0.64) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL13803965 | 0.82 | DPP4 (0.63) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL8251913 | 0.79 | DPP4 (0.49) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL4168851 | 0.78 | DPP4 (0.64) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL13803963 | 0.78 | DPP4 (0.55) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL13804096 | 0.77 | DPP4 (0.51) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL8248410 | 0.74 | DPP4 (0.66) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL4168303 | 0.74 | DPP4 (0.66) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL4167916 | 0.74 | DPP4 (0.66) | DPP4FAPDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 54/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.